Pharmafit Provence
OLIGOSOL Zinc Nickel Cobalt Oral solution in ampoule 28Amp/2ml

OLIGOSOL Zinc Nickel Cobalt Oral solution in ampoule 28Amp/2ml

VIDAL information
Your professional account

PharmaFit supplies pharmacies and healthcare professionals. Access your purchasing terms and availability through your professional account.

Access is reserved for authorised professionals, following account approval.

Contact PharmaFit

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 15/07/2020

ZINC-NICKEL-COBALT OLIGOSOL, drinkable solution in ampoule


Forms and presentations

Oral solution.
Ampoule with two self-breaking tips of 2 ml. Box of 28.


Composition

For one ampoule of 2 ml:

Zinc gluconate: 0,470 mg
(Corresponding quantity of zinc: 0,0674 mg)

Nickel gluconate: 0,555 mg
(Corresponding quantity of nickel: 0,0726 mg)

Cobalt gluconate: 0,553 mg
(Corresponding quantity of cobalt: 0,0726 mg)

Excipient with known effect: glucose (100 mg in one ampoule of 2 ml).


Excipients:

Anhydrous glucose, purified water.



Indications

Used as a constitutional modifier, particularly in cases of a slimming diet.



Dosage and administration

Dosage

FOR ADULTS ONLY.

2 to 3 ampoules per day.

The ampoules are to be taken:

  • preferably in the morning on an empty stomach,
  • possibly 15 minutes before a meal or in the evening at bedtime.

Method of administration

Oral use.

Sublingual administration is recommended: keep the contents of the ampoule under the tongue for 1 to 2 minutes before swallowing.



Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section Composition.



Warnings and precautions

Treatment with these trace mineral elements does not replace any specific treatment that may be required.

This medicine contains glucose. Its use is not recommended in patients with glucose-galactose malabsorption syndrome.



Interactions

The data available to date do not suggest the existence of clinically significant interactions.



Fertility, pregnancy and breastfeeding

In the absence of experimental and clinical data, and as a precaution, use of this medicine should be avoided during pregnancy and breastfeeding.



Adverse effects

Skin and subcutaneous tissue disorders under treatment but do not allow establishing whether these are true allergies. The frequency of occurrence cannot be determined.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr.



Overdose

No cases of overdose have been reported.



Pharmacodynamics

Pharmacotherapeutic class: OLIGOTHERAPY (V: various)

Trace mineral element.



Shelf life

5 years.



Special storage precautions

Store at a temperature below 25 °C.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400937547802 (28Amp/2ml).
Not reimbursed by Social Security.
 
Marketing authorisation holder: Labcatal, 1198 avenue Docteur Maurice Donat, Zac du Fond de l'Orme, 06250 Mougins.

GRANIONS EA-PHARMA Laboratory
Le Parador II
5, allée Crovetto-Frères. 98000 Monaco
Tel: 00 377 92 05 76 30

Source: VIDAL · Updated on 11/11/2026. This information does not replace advice from a healthcare professional.